Russell Investments Group
CBIO

Russell Investments Group’s Crescent Biopharma CBIO Stock Holding History

Russell Investments Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1K Buy
+1,726
New +$33.7K ﹤0.01% 3728
2021
Q1 		– Sell
-902
Closed -$338K – 3140
2020
Q4 		$338K Buy
902
+841
+1,379% +$295K ﹤0.01% 2578
2020
Q3 		$18K Sell
61
-163
-73% -$62.3K ﹤0.01% 3141
2020
Q2 		$83K Buy
+224
New +$63.4K ﹤0.01% 2921
2017
Q3 		– Sell
-314
Closed -$350K – 2968
2017
Q2 		$350K Buy
314
+199
+173% +$164K ﹤0.01% 2539
2017
Q1 		$63K Sell
115
-168
-59% -$103K ﹤0.01% 2874
2016
Q4 		$172K Buy
+283
New +$177K ﹤0.01% 2744

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Russell Investments Group's CBIO Position: Q2 2026 in Review

Russell Investments Group opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 1,726 shares worth $31.1K. The stake represents ﹤0.01% of the portfolio and ranks #3728 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in CBIO as recently as Q4 2020.

Russell Investments Group first reported a position in CBIO in Q4 2016 and has held it in 7 quarters since. The position peaked at $350K in Q2 2017. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Russell Investments Group held 1,726 shares of Crescent Biopharma worth $31.1K as of Q2 2026.
  • Crescent Biopharma was a new Russell Investments Group position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3728 holding.
  • Russell Investments Group first reported a position in Crescent Biopharma in Q4 2016 and has held it in 7 quarters since.
  • Russell Investments Group's Crescent Biopharma position peaked at $350K in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.